PharmaGossip (quoting Business Week) details that Sanofi's purchase of Shantha's vaccine business has fallen down and can't get up - at least without losing a $340 M WHO contract. WHO cancelled its order of Shan5 for the United Nations Children's Fund after repeated manufacturing quality problems.
This is another set back to the near term revenue picture for Sanofi which is grappling with its pipeline issues and upcoming patent cliff. This makes it all the more desirable for Sanofi to get on with its Genzyme acquisition to start filling in the hole.
Posted by Bruce Lehr November 15th 2010.